Table 1.
Baseline patient characteristics
| Variable | PM(44) | No PM(184) | P = |
|---|---|---|---|
| Age (yrs, range) | 63(44–79) | 61(23–82) | 0.35 |
| Male | 30(68%) | 139(76%) | 0.32 |
| BMI > 30 | 15(34%) | 77(42%) | 0.39 |
| Caucasian | 35(80%) | 133(72%) | 0.57 |
| Prior nephrectomy | 34(77%) | 109(59%) | 0.03 |
| Diabetes | 27(61%) | 55(36%) | 0.001 |
| Hypertension | 24(55%) | 85(46%) | 0.32 |
| Number of metastases | 3 (1–5) | 3 (1–4) | 0.001 |
| 1 | 4(9%) | 57(31%) | |
| 2 | 10(23%) | 74(40%) | |
| ≥3 | 30(68%) | 53(29%) | |
| Sites of Metastases | |||
| Lung | 30(68%) | 139(76%) | 0.34 |
| Bone | 13(30%) | 60(33%) | 0.52 |
| Liver | 12(27%) | 39(21%) | 0.39 |
| Brain | 5(11%) | 25(14%) | 0.69 |
| Adrenal | 12(27%) | 26(14%) | 0.38 |
| MSKCC group | 0.04 | ||
| Good | 9(20%) | 14(8%) | |
| Intermediate | 27(62%) | 135(73%) | |
| Poor | 8(18%) | 35(19%) | |
| Heng* | 0.04 | ||
| Intermediate | 32(73%) | 158(86%) | |
| Poor | 12(27%) | 26(14%) | |
| ECOG | 0.71 | ||
| 0 | 13(30%) | 46(25%) | |
| 1 | 23(52%) | 107(58%) | |
| ≥2 | 8(18%) | 31(17%) | |
| Hb (< LLN) | 31(70%) | 143(78%) | 0.32 |
| Corrected Calcium (> LLN) | 8(18.2%) | 33(18%) | 0.56 |
| Platelets (> ULN) | 25(57%) | 98(53%) | 0.50 |
| LDH (> 1.5 ULN) | 18(41%) | 80(44%) | 0.6 |
| ANC (> ULN) | 11(25%) | 55(30%) | 0.7 |
| Diagnosis to treatment < 1 year | 21(48%) | 120(65%) | 0.05 |
*
No patients in Heng – Good prognostic cohort